Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor modified T cell infusions for liver metastases

INTRODUCTION: Our phase I Hepatic Immunotherapy for Metastases (HITM) trial tested the safety of chimeric antigen receptor modified T cell (CAR-T) hepatic artery infusions (HAI) for unresectable CEA+ liver metastases (LM). High neutrophil:lymphocyte ratios (NLR) predict poor outcome in cancer patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Saied, Abdul, Licata, Lauren, Burga, Rachel A., Thorn, Mitchell, McCormack, Elise, Stainken, Brian F., Assanah, Earle O., Khare, Pranay D., Davies, Robin, Espat, N. Joseph, Junghans, Richard P., Katz, Steven C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245365/
https://www.ncbi.nlm.nih.gov/pubmed/25277132
http://dx.doi.org/10.1038/cgt.2014.50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245365/
https://www.ncbi.nlm.nih.gov/pubmed/25277132
http://dx.doi.org/10.1038/cgt.2014.50

Ejemplares similares